Legal Proceedings	6 Months Ended
Jun. 25, 2022
Legal Proceedings [Abstract]
Legal Proceedings	Note 9 – Legal Proceedings Henry Schein, Inc. has been named as a defendant in multiple lawsuits (currently less than one-hundred and fifty ( 150 ); in less than half of those cases one or more of Henry Schein, Inc.’s subsidiaries is also named as a defendant). Generally, the lawsuits allege that the manufacturers of prescription opioid drugs engaged in a false advertising campaign to expand the market for such drugs and their own market share and that the entities in the supply chain (including Henry Schein, Inc and its affiliated companies) reaped financial rewards by refusing or otherwise failing to monitor appropriately and restrict the improper distribution of those drugs. These actions consist of some that have been consolidated within the MultiDistrict Litigation (“MDL”) proceeding In Re National Prescription Opiate Litigation (MDL No. 2804; Case No. 17-md-2804) and are currently stayed, and others which remain pending in state courts and are proceeding independently and outside of the MDL. At this time, the following cases are set for trial: the action filed by Mobile County Board of Health, et al., in Alabama state court, which is currently set for a jury trial on January 9, 2023; the action filed by DCH Health Care Authority, et al. in Alabama state court, which is currently scheduled for a jury trial on July 24, 2023; and the action filed by Florida Health Sciences Center, Inc. (and 38 other hospitals located throughout the State of Florida) in Florida state court, which is currently scheduled for a jury trial in October 2024. In June 2022, we settled twenty-six cases filed by hospitals in West Virginia, and settled with one additional hospital, for a total amount of three-hundred thousand dollars. The twenty-six cases have been dismissed. Of Henry Schein’s 2021 sales of approximately $ 12.4 billion, sales of opioids represented less than two-tenths of 1 percent. Opioids represent a negligible part of our business. We intend to defend ourselves vigorously against these actions. From time to time, we may become a party to other legal proceedings, including, without limitation, product liability claims, employment matters, commercial disputes, governmental inquiries and investigations (which may in some cases involve our entering into settlement arrangements or consent decrees), and other matters arising out of the ordinary course of our business. While the results of any legal proceeding cannot be predicted with certainty, in our opinion none of these other pending matters are currently anticipated to have a material adverse effect on our consolidated financial position, liquidity or results of operations. As of June 25, 2022, we had accrued our best estimate of potential losses relating to claims that were probable to result in liability and for which we were able to reasonably estimate a loss. This accrued amount, as well as related expenses, was not material to our financial position, results of operations or cash flows. Our method for determining estimated losses considers currently available facts, presently enacted laws and regulations and other factors, including probable recoveries from third parties.

Henry Schein, Inc. has been named as a defendant in multiple lawsuits

(currently less than one-hundred and fifty

(

150

); in less than half of those cases one or more of Henry Schein,

Inc.’s subsidiaries is also named as a

defendant).

Generally, the lawsuits allege that the manufacturers of prescription opioid drugs engaged in a false

advertising campaign to expand the market for such drugs and their own

market share and that the entities in the

supply chain (including Henry Schein, Inc and its affiliated companies) reaped financial

rewards by refusing or

otherwise failing to monitor appropriately and restrict the improper distribution

of those drugs.

These actions

consist of some that have been consolidated within the MultiDistrict Litigation

(“MDL”) proceeding In Re National

Prescription Opiate Litigation (MDL No. 2804; Case No. 17-md-2804)

and are currently stayed, and others which

remain pending in state courts and are proceeding independently and outside

of the MDL.

At this time, the

following cases are set for trial: the action filed by Mobile County Board

of Health, et al., in Alabama state court,

which is currently set for a jury trial on January 9, 2023; the action filed

by DCH Health Care Authority, et al. in

Alabama state court, which is currently scheduled for a jury trial on July 24, 2023;

and the action filed by Florida

Health Sciences Center, Inc. (and

other hospitals located throughout the State of Florida) in

Florida state court,

which is currently scheduled for a jury trial in October 2024.

In June 2022, we settled

twenty-six

cases filed by

hospitals in West Virginia,

and settled with

one

additional hospital, for a total amount of

three-hundred thousand

dollars.

The

twenty-six

cases have been dismissed.

Of Henry Schein’s 2021 sales of approximately $

12.4

billion,

sales of opioids represented less than

two-tenths

of 1 percent.

Opioids represent a negligible part of our business.

We intend to defend ourselves vigorously against these actions.

From time to time, we may become a party to other legal proceedings,

including, without limitation, product

liability claims, employment matters, commercial disputes, governmental

inquiries and investigations (which may

in some cases involve our entering into settlement arrangements or consent

decrees), and other matters arising out

of the ordinary course of our business.

While the results of any legal proceeding cannot be predicted with certainty,

in our opinion none of these other pending matters are currently

anticipated to have a material adverse effect on our

consolidated financial position, liquidity or results of operations.

As of June 25, 2022, we had accrued our best estimate of potential

losses relating to claims that were probable to

result in liability and for which we were able to reasonably estimate a

loss.

This accrued amount, as well as related

expenses, was not material to our financial position, results of operations

or cash flows.

Our method for

determining estimated losses considers currently available

facts, presently enacted laws and regulations and other

factors, including probable recoveries from third parties.